{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:35:15Z","timestamp":1783427715025,"version":"3.54.6"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,21]]},"DOI":"10.7759\/cureus.90684","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:25:26Z","timestamp":1755797126000},"source":"Crossref","is-referenced-by-count":6,"title":["Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Non-diabetic Heart Failure: A Systematic Review of Randomized Controlled Trials and Real-World Evidence"],"prefix":"10.7759","author":[{"given":"Mohammed O","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama M","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagwa M","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure","volume":"3","author":"Savarese G","year":"2017","unstructured":"Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017, 3:7-11. 10.15420\/cfr.2016:25:2","journal-title":"Card Fail Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray JJ","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014, 371:993-1004. 10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski P","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al.. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016, 37:2129-200. 10.1093\/eurheartj\/ehw128","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"79","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2022, 79:e263-421. 10.1016\/j.jacc.2021.12.012","journal-title":"J Am Coll Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition - a novel strategy for diabetes treatment","volume":"9","author":"Chao EC","year":"2010","unstructured":"Chao EC, Henry RR. SGLT2 inhibition - a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010, 9:551-9. 10.1038\/nrd3180","journal-title":"Nat Rev Drug Discov"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal B","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al.. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017, 377:644-57. 10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-57. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020, 383:1413-24. 10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker SD","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al.. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021, 385:1451-61. 10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma S","year":"2018","unstructured":"Verma S, McMurray JJ. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018, 61:2108-17. 10.1007\/s00125-018-4670-7","journal-title":"Diabetologia"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer M","year":"2022","unstructured":"Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis. Circulation. 2022, 146:1383-405. 10.1161\/CIRCULATIONAHA.122.061732","journal-title":"Circulation"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini E","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis. Diabetes Care. 2016, 39:1108-14. 10.2337\/dc16-0330","journal-title":"Diabetes Care"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.040514","article-title":"The serendipitous story of SGLT2 inhibitors in heart failure","volume":"139","author":"Verma S","year":"2019","unstructured":"Verma S, McMurray JJV. The serendipitous story of SGLT2 inhibitors in heart failure. Circulation. 2019, 139:2537-41. 10.1161\/CIRCULATIONAHA.119.040514","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(17)30258-9","article-title":"Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis","volume":"5","author":"Birkeland KI","year":"2017","unstructured":"Birkeland KI, J\u00f8rgensen ME, Carstensen B, et al.. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017, 5:709-17. 10.1016\/s2213-8587(17)30258-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.039177","article-title":"Empagliflozin and the risk of heart failure hospitalization in routine clinical care","volume":"139","author":"Patorno E","year":"2019","unstructured":"Patorno E, Pawar A, Franklin JM, et al.. Empagliflozin and the risk of heart failure hospitalization in routine clinical care. Circulation. 2019, 139:2822-30. 10.1161\/CIRCULATIONAHA.118.039177","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry","volume":"72","author":"Greene SJ","year":"2018","unstructured":"Greene SJ, Butler J, Albert NM, et al.. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry. J Am Coll Cardiol. 2018, 72:351-66. 10.1016\/j.jacc.2018.04.070","journal-title":"J Am Coll Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021, 42:3599-726. 10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis","volume":"18","author":"Haddaway NR","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev. 2022, 18:e1230. 10.1002\/cl2.1230","journal-title":"Campbell Syst Rev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref23","unstructured":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (2011). Accessed. July 31, 2025: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction","volume":"77","author":"Santos-Gallego CG","year":"2021","unstructured":"Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al.. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021, 77:243-55. 10.1016\/j.jacc.2020.11.008","journal-title":"J Am Coll Cardiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"Jhund PS","year":"2022","unstructured":"Jhund PS, Kondo T, Butt JH, et al.. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med. 2022, 28:1956-64. 10.1038\/s41591-022-01971-4","journal-title":"Nat Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080925","article-title":"SGLT-2 inhibitors and mortality among patients with heart failure with reduced ejection fraction: linked database study","volume":"387","author":"Svanstr\u00f6m H","year":"2024","unstructured":"Svanstr\u00f6m H, Mkoma GF, Hviid A, Pasternak B. SGLT-2 inhibitors and mortality among patients with heart failure with reduced ejection fraction: linked database study. BMJ. 2024, 387:e080925. 10.1136\/bmj-2024-080925","journal-title":"BMJ"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink HJ","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016, 134:752-72. 10.1161\/CIRCULATIONAHA.116.021887","journal-title":"Circulation"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee TM","year":"2017","unstructured":"Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017, 104:298-310. 10.1016\/j.freeradbiomed.2017.01.035","journal-title":"Free Radic Biol Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation","volume":"61","author":"Uthman L","year":"2018","unstructured":"Uthman L, Baartscheer A, Bleijlevens B, et al.. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia. 2018, 61:722-6. 10.1007\/s00125-017-4509-7","journal-title":"Diabetologia"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/imj.16440","article-title":"General physicians' perspectives on SGLT2 inhibitors for heart failure","volume":"54","author":"Teng LE","year":"2024","unstructured":"Teng LE, Lammoza N, Aung AK, et al.. General physicians' perspectives on SGLT2 inhibitors for heart failure. Intern Med J. 2024, 54:1483-9. 10.1111\/imj.16440","journal-title":"Intern Med J"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.80610","article-title":"Adoption and prescribing practices of sodium-glucose transport protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) agonists in cardiology: a cross-sectional study in Saudi Arabia","volume":"17","author":"Jamsheer F","year":"2025","unstructured":"Jamsheer F, Alahmed A, Alshamlan N, Abdali N, Aljarmal M, Alsudairy N. Adoption and prescribing practices of sodium-glucose transport protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) agonists in cardiology: a cross-sectional study in Saudi Arabia. Cureus. 2025, 17:e80610. 10.7759\/cureus.80610","journal-title":"Cureus"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors AA","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, et al.. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022, 28:568-74. 10.1038\/s41591-021-01659-1","journal-title":"Nat Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/402415-sodium-glucose-cotransporter-2-sglt2-inhibitors-in-non-diabetic-heart-failure-a-systematic-review-of-randomized-controlled-trials-and-real-world-evidence","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:25:27Z","timestamp":1755797127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/402415-sodium-glucose-cotransporter-2-sglt2-inhibitors-in-non-diabetic-heart-failure-a-systematic-review-of-randomized-controlled-trials-and-real-world-evidence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.90684","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,21]]}}}